| Name | Title | Contact Details |
|---|
Vitae Pharmaceuticals, Inc. focuses on discovering and developing drugs for various diseases. Its product candidates include VTP-34072, which is in a Phase II clinical trial for the treatment of type 2 diabetes; and VTP-37948 that is in Phase I clinical trials for alzheimer's disease. The company’s products in preclinical studies comprise VTP-43742 for the treatment of autoimmune disorders, such as psoriasis, multiple sclerosis, rheumatoid arthritis, Behcet's disease, and autoimmune uveitis; VTP-38443 for the treatment of acute coronary syndrome that consists of unstable angina and heart attacks; and VTP-38543 for the treatment of atopic dermatitis, an immune system mediated inflammation of the skin. Vitae Pharmaceuticals, Inc. has collaborations with Boehringer Ingelheim GmbH for the development of VTP-34072 and VTP-37948. Vitae Pharmaceuticals, Inc. was formerly known as Concurrent Pharmaceuticals, Inc. and changed its name to Vitae Pharmaceuticals, Inc. in January, 2005. The company was founded in 2001 and is headquartered in Fort Washington, Pennsylvania.
Discover Echo redefines traditional microscope design. Experience our award-winning Automated, Fluorescence, and Transmitted Light Microscopes.
BH1 (Better Health for Everyone) is a Franklin, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
TissueVision Inc. (TVI) is a multi-disciplinary life sciences company offering 3D tissue imaging and analysis solutions for the research market. Our powerful Serial Two-Photon Plus (STP²) platform features stunning high-resolution multispectral datasets and analysis pipelines that create reliable 3D tissue models. The indexed histological sections produced during the STP² process can be further investigated with secondary analyses that run the gamut from standard histological stains to advanced spatial genomics. The final result is rich, multiplexed 3D models that deliver actionable and quantitative results. TVI provides project design, GLP-like documentation, including full protocol and report generation, and quality control review measures of all study-related materials. TVI is a solution provider to help answer research questions in a variety of therapeutic areas, including neuroscience, cancer, neurodegeneration, ophthalmology, and dermatology.
Botanix Pharmaceuticals is a biotechnology company listed on the ASX (ASX: BOT) with headquarters in Perth, Australia, and Philadelphia, USA. The company specializes in clinical-stage dermatology and antimicrobial treatments, focusing on synthetic cannabinoid-based therapies that utilize cannabidiol (CBD) and its proprietary skin-delivery technology, Permetrex™. The companys product pipeline includes several innovative therapies aimed at addressing common dermatological conditions. These include BTX 1503 for moderate-to-severe acne, BTX 1702 for rosacea, and BTX 1204A for moderate atopic dermatitis. Additionally, BTX 1801 targets infections in hemodialysis patients and other antimicrobial applications. All products leverage the Permetrex™ delivery system to enhance skin absorption, and Botanix is also exploring veterinary applications for atopic dermatitis. Botanix aims to improve patient outcomes by addressing unmet needs in dermatology and antimicrobial resistance, positioning itself as a leader in cannabinoid-based dermatological treatments.